secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016452
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M
---------------------------------------------------------------------------

- Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.
- Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.
- Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.
- Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.
- MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/0001437749-25-016452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/zvra20250106_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer